Erdafitinib Plus Cetrelimab Elicits Durable Responses in Met

Erdafitinib alone or in combination with cetrelimab has shown activity in patients with FGFR-altered metastatic urothelial carcinoma.

Related Keywords

Houston , Texas , United States , Arleneo Siefker Radtke , , University Of Texas Md Anderson Cancer Center , Cancer Center ,